Miltenyi Biotec
Miltenyi Biotec home - back to start page
Home ¦ Contact ¦ Ordering ¦ Terms & conditions ¦ Legal notes ¦ Jobs ¦ Forum ¦ Business development ¦ Sitemap
Miltenyi Biotec home - back to start page
Miltenyi Biotec home - back to start page
Miltenyi Biotec
MACS® Cell SeparationMiltenyi BiotecMACS® Cell AnalysisMiltenyi BiotecMACS® Cell CultureMiltenyi BiotecMACSmolecularMiltenyi BiotecClinical ProductsMiltenyi BiotecIndustrial ServicesMiltenyi BiotecMiltenyi BiotecCustomer supportMiltenyi BiotecCompany

Miltenyi Biotec
MACS® Tools for neuroscience research
Tregs—the complete portfolio
Comprehensive Genomics Services, just send your samples…
Baxter products
MACS Cytokines and Growth Factors
MACS eNewsletter
Subscribe to the
MACS eNewsletter
for regular product information via e-mail.
Miltenyi Biotec
CD326 (EpCAM) MicroBeads
Description
The MicroBead-coupled CD326 antibody recognizes the human epithelial antigen (HEA), an epithelial cell–specific adhesion molecule, also known as epithelial cell adhesion molecule (EpCAM) or epithelial-specific antigen (ESA). The CD326 antigen is broadly expressed on cells of epithelial origin and on epithelium-derived tumor cells1. In order to prevent Fc receptor–mediated non-specific labeling of non-epithelial cells, it is strongly recommended to use FcR Blocking Reagent before magnetic labeling.
Applications
CD326 (EpCAM) MicroBeads can be used for the positive selection of viable epithelial tumor cells from peripheral blood, bone marrow, lymphoid tissue, serous effusions and stool samples11 of patients with carcinomas. Tumor cells enriched by CD326 (EpCAM) MicroBeads can be cultured2 and analyzed by immunocytochemistry3–7, flow cytometry8, or molecular biology techniques, for example, RT-PCR9. Primary tumor cell cultures have been purified using CD326 (EpCAM) MicroBeads10. Hepatic stem cells have also been isolated using MACS® Technology by selection for CD326 (EpCAM) expression.12
Columns
MS, LS, XS Columns, or autoMACSâ„¢ Columns.
 
Figure 1
CD326 (EpCAM)+ tumor cells isolated from pleural effusion of a patient with adeno-carcinoma using CD326 (EpCAM) MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells were stained with CD326 (EpCAM)-FITC and Anti-FITC Alkaline Phosphatase plus substrate. (Courtesy of Dr. Motherby and Prof. Böcking, Inst. of Cytopathol., Univ. Düsseldorf, Germany.)
Figure 2
Enrichment of tumor cells from PBMCs spiked with cells of the breast cancer cell line BT474. Separation was performed using an MS Column and CD326 (EpCAM) MicroBeads.
A: Cell mixture before separation (6×107 PBMCs were mixed with 50,000 tumor cells)
B: Positive fraction with enriched breast cancer cells (1.54×105 total cells)
Miltenyi Biotec
Customer login
Customer login
Forgot your password?
New customer?
Get more information
My favorites
Your current favorite list is empty.
Products
CD326 (EpCAM) MicroBeads, human
For research use only
for 109 total cells
Download data sheet
130-061-101
Qty:
 

CD326 (EpCAM) MicroBeads + CD326 (EpCAM)-PE, human
For research use only
for 109 total cells
for 100 tests with 107 total cells
Download data sheet #1
Download data sheet #2
130-092-234
Qty:
 

Related products
FcR Blocking Reagent, human (#130-059-901)
Anti-ErbB-2 MicroBeads, human (#130-090-482)
CD45 MicroBeads, human (#130-045-801)
Inside Stain Kit (#130-090-477)
CD326 (EpCAM) Antibodies
Anti-Cytokeratin-Alkaline Phosphatase, human (#130-090-462)
Anti-Cytokeratin (CK3-6H5) Antibodies
Anti-Cytokeratin (CK3-3E4) Antibodies
CD45 Antibodies
MACS References
1. Moldenhauer et al. (1987) Br. J. Cancer 56: 714–721.[7147]
2. Leinung et al. (2000) Langenbeck´s Arch. Surg. 385: 337–343.[986]
3. Krüger et al. (1999) Cytotherapy 1: 135–139.[568]
4. Krüger et al. (2000) Transfusion 40: 1489–1493.[984]
5. Krüger et al. (2001) J. Hematother. Stem Cell Res. 10: 141–145.[985]
6. Witzig et al. (2002) Clin. Cancer Res. 8: 1085–91.[2176]
7. Fehm et al. (2002) Clin. Cancer Res. 8: 2073–84.[4243]
8. Garau et al. (1997) Europ. J. Histochem. 41(S2): 18–19.[378]
9. Ellis et al. (2003) Urology 61: 277–281.[3990]
10. Chan, J.K. et al. (2006) Clin. Cancer Res. 12(6): 1859–1867.[11130]
11. Lewin, M.H. et al. (2006) Cancer Res. 66(3): 1859–1865.[11129]
12. Laurson, J. et al. (2005) Int. J. Exp. Pathol. 68: 1–18.[7717]
Miltenyi Biotec
© 1999 - 2008 Miltenyi Biotec
Miltenyi Biotec